Key Stats for Organon Stock
- Current Price: $13.16
- Deal Price (Cash): $14.00 per share
- TIKR Mid-Case Target: $12.79
- Potential Standalone Total Return (Mid): (2.8%)
- Annualized Standalone IRR (Mid): (0.6%) / year
- Deal Enterprise Value: $11.75 billion
- Merger Spread: ~$0.84 (~6.4% to deal price)
- Expected Close: Early 2027
- Q4 2025 Earnings Reaction: +4.67% (February 12, 2026)
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Organon (OGN) went from a distressed spinoff to a confirmed acquisition target in under a month. The stock hit a 52-week low of $5.69 before closing Monday at $13.16, up 16.87% on the day Sun Pharmaceutical Industries confirmed it would acquire Organon for $14.00 per share in cash.
That price represents a 103% premium to the April 9 close, per the terms of the definitive agreement filed with the SEC.
The deal had been telegraphed by weeks of acquisition chatter, with competing interest from Grunenthal and private equity firms before Sun locked it up. At $11.75 billion in enterprise value, it is the largest overseas acquisition ever made by an Indian pharmaceutical company, according to Sun Pharma’s own announcement.
Organon Board Chair Carrie Cox said in the joint press release: “Following a comprehensive review of strategic alternatives, our Board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders.”
The Q4 2025 earnings call made the strategic logic clear. Interim CEO Joe Morrissey told investors: “In 2026, our primary objective is to maintain performance that aligns with last year.”
That is not a growth story. Add $8.2 billion in net debt and additional compliance matters disclosed by the Audit Committee, and a strategic sale was the most viable path forward.
See historical and forward estimates for Organon stock (It’s free!) >>>
Is Organon Undervalued Today?
The TIKR standalone model answers this directly. The mid-case projects OGN at $12.79 by 12/31/30, a negative total return of (2.8%), and an annualized IRR of (0.6%) per year from today’s price. Sun Pharma’s $14 cash offer beats the standalone mid-case outright, in cash, without the five-year wait or the execution risk.
Even the TIKR high case only reaches around $15 by 12/31/30, a 13.4% total return over more than four years. Against that, $14 in cash closing in early 2027 is a compelling trade-off for most shareholders.
On a valuation multiples basis, the deal is priced below peers. At the $11.75 billion enterprise value, Sun Pharma is paying at a NTM EV/EBITDA of 6.14x, per TIKR. Viatris, the closest comparable in the established-brands and biosimilars space, trades at 7.04x NTM EV/EBITDA on TIKR’s Competitors page. Teva trades at 9.86x. Organon’s discount reflects its debt load, not a gap in business quality, which is exactly why Sun Pharma is getting a deal.
That debt load is the clearest argument that the $14 offer is fair rather than a lowball. LTM net debt stands at $8,226 million per TIKR, with a net debt/EBITDA ratio of 4.77x.
CFO Matt Walsh confirmed on the Q4 2025 earnings call that the company’s 2026 goal was to bring leverage below 4x, aided by $390 million in proceeds from the January 2026 Jada divestiture.
Sun Pharma plans to fund the deal through internal cash and committed bank financing, targeting post-transaction net leverage of 2.3x. That path is only achievable at Sun’s scale, not Organon’s.
The Street had already given up on a standalone recovery. TIKR’s Street Targets data shows a mean price target of $10.40 from 5 analysts as of April 27, 2026, with the breakdown at 1 Outperform, 2 Holds, and 2 Underperforms. The $14 deal price is 34% above the consensus, meaning Sun Pharma is paying more than the sell side believed the business was worth on its own.
See how Organon performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $13.16
- TIKR Mid-Case Target: $12.79
- TIKR High-Case Target: ~$15
See analysts’ growth forecasts and price targets for Organon stock (It’s free!) >>>
The TIKR mid-case uses around 0.4% annual revenue CAGR, which reflects the push and pull Walsh described on the Q4 call. Vtama, Organon’s topical treatment for plaque psoriasis and atopic dermatitis, delivered $128 million in 2025 revenue and is expected to grow around 20-25% in 2026. Hadlima, its adalimumab biosimilar, grew 61% on a constant-currency basis in 2025. Those gains are offset by Nexplanon’s near-term volume dip from its transition to a five-year label, which eliminates the roughly 13% of annual insertions that were reinsertions. Walsh confirmed 2026 is the most pronounced year for that headwind.
The pressure on margins and free cash flow is just as real. LTM interest expense is $504 million per TIKR, and the 2026 non-GAAP tax rate is guided to 27.5-29.5% following OECD Pillar 2 implementation. LTM free cash flow was $538 million per TIKR. Those constraints cap what Organon could return to shareholders independently.
For investors holding OGN at today’s $13.16, the standalone high case is around $15 by 12/31/30. The deal offers $14 in cash in roughly nine months. The ~$0.84 merger spread, about 6.4%, is the price of deal risk: regulatory approvals across multiple jurisdictions and an Organon stockholder vote both stand between now and close.
Conclusion
Watch the Q1 2026 earnings call on May 7, 2026. It is the first management update since the deal was signed. The number to watch: whether adjusted EBITDA margin holds at or above the Q4 2025 level of 25.4%, which would confirm the business is stable enough to reach close without complication.
Sun Pharma is acquiring a global commercial platform below peer multiples. OGN shareholders receive cash that exceeds standalone analyst targets by over 30%. The only remaining question is whether the deal closes on schedule.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Organon?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Organon, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Organon alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Organon on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
